Temporal Artery Biopsy Debate: Positive TAB Result Prolongs Steroid Use in Giant Cell Arteritis

Temporal artery biopsy (TAB) in diagnosing giant cell arteritis has been criticized due to surgical risks, a high false negative rate, and redundant information when patients already met American College of Rheumatology criteria. The objective of this study was to investigate TAB's impact on steroid treatment duration. A retrospective chart review garnered patient demographics, symptoms, comorbidities, and steroid treatment duration in patients undergoing TAB at a single center. Steroid treatment was compared between TAB+ and TAB - patients. One hundred seven patients undergoing TAB were included. Patients were predominantly women (70.1%) with a median age of 74 years (46 -91). Of 107 TAB results, 74 (69.2%) were negative, 23 (21.5%) were positive, and 10 (9.3%) were found to be indeterminate. In TAB+ patients, the mean erythrocyte sedimentation rate was not significantly different than TAB - patients (60.2 versus 43.7, = 0.45), nor was the median C-reactive protein (38.8 versus 18.1, = 0.17). Regarding steroid use, both TAB+ and TAB - patients had a similarly high rate of prebiopsy steroid initiation (82.6% versus 70.3%, = 0.32). More TAB+ patients remained on steroids at 6 weeks (95.0% versus 57.4%, = 0.004), 6 months (95% versus 37.7%, < 0.001), 1 year (65.0% versus 31.1%, = 0.024), and 18 months (50.0% versus 19.7%, = 0.045). By 2 years, the difference no longer met significance (35.0% versus 14.8%, = 0.12). = 0.12). TAB positivity does seem to influence maintenance of steroids up to 18 months after biopsy.